At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Acalabrutinib (drug)
- How long the study runs
- Study runs about 54 months (dates as stated)
- About the drug or intervention
- Acalabrutinib — drug: Acalabrutinib
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years to 130 Years
- Who
- All
- Number of participants
- 287
- Started
- 2022-10-17
- Last checked
- 2026-08
Plain English Summary
What is this study?
- • Testing a new treatment for chronic lymphocytic leukemia, cll
- • Clinical study - 287 participants
- • This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study)
Who can take part?
- • Ages 18 Years to 130 Years
- • Diagnosed with chronic lymphocytic leukemia, cll
Where?
- • Aylesbury - Research Site
- • Bath - Research Site
- • Birmingham - Research Site
- • Bournemouth - Research Site
- • +25 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study). Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients. Clinical data will be extracted from the patients' clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as part of the UK acalabrutinib EAP.
More detail
1. Primary Objectives: a. To estimate real-world progression-free survival in patients with CLL who received acalabrutinib in the first-line. 2. Secondary Objectives: 1. To estimate real-world overall survival in patients with CLL who received acalabrutinib in the first-line. 2. To describe real-world response rate to acalabrutinib in patients with CLL who received acalabrutinib in the first-line. 3. To describe the healthcare resource utilisation in patients with CLL who received acalabrutinib in the first-line. 4. To describe post-progression treatment patterns in patients with CLL who progressed from first-line acalabrutinib. 5. To describe real-world clinical progression free survival in patients with CLL who received acalabrutinib in the first-line and progressed during acalabrutinib treatment. 6. To describe acalabrutinib treatment patterns in patients with CLL who received acalabrutinib in the first-line. 7. To describe baseline clinical and demographic characteristics in patients with CLL who received acalabrutinib in the first-line.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 130 Years
- Who can join: All genders
What the study is looking for
- ✓Treatment-naïve CLL patients who were initiated on acalabrutinib as part of the UK Early Access Programme
- ✓Received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021
- ✓Patients aged ≥18 years old
- ✓Note: patients later found to have small lymphocytic lymphoma (SLL) may also be included in the EAP.
Who cannot take part
- ✗\- None listed in study protocol
See the full criteria
Where Is This Study? (29 UK sites)
Research Site
Aylesbury, United Kingdom
Research Site
Bath, United Kingdom
Research Site
Birmingham, United Kingdom
Research Site
Bournemouth, United Kingdom
Research Site
Cardiff, United Kingdom
Research Site
Cornwall, United Kingdom
Research Site
Dartford, United Kingdom
Research Site
Derby, United Kingdom
Research Site
Doncaster, United Kingdom
Research Site
Dorset, United Kingdom
Research Site
Eastbourne, United Kingdom
Research Site
Hull, United Kingdom
Research Site
Leicester, United Kingdom
Research Site
Lincoln, United Kingdom
Research Site
Liverpool, United Kingdom
Research Site
London SE1 9RT, United Kingdom
Research Site
London W12 OHS, United Kingdom
Research Site
Mid Yorkshire, United Kingdom
Research Site
Middlesbrough, United Kingdom
Research Site
Newcastle, United Kingdom
Research Site
North Shields, United Kingdom
Research Site
Norwich, United Kingdom
Research Site
Nottingham, United Kingdom
Research Site
Oxford, United Kingdom
Research Site
Plymouth, United Kingdom
Research Site
Southampton, United Kingdom
Research Site
Stockton-on-Tees, United Kingdom
Research Site
Stoke-on-Trent, United Kingdom
Research Site
Wigan, United Kingdom
How to Get in Touch
AstraZeneca Clinical Study Information Center
Sponsor contactCONTACT